loader image
Wednesday, October 8, 2025
75.6 F
McAllen
- Advertisement -

Nationally Recognized Bladder Cancer Surgeon Dr. Robert Svatek Visits DHR Health

Translate to Spanish or other 102 languages!

DHR Health Urology Insitute physicians with Dr. Svatek during visit.  Left to Right: Dr. Henry Ruiz, Medical Director at DHR Health Urology Insitute, Dr. Robert Svatek, Chair of Urology at UTHSCSA, Dr. Gustavo Villegas, Dr. Maria Rodriguez, and Dr. Gaudencio Olguin.

Mega Doctor News

- Advertisement -

Edinburg, TX – Dr. Robert Svatek, the Chair of Urology at UT Science Center at San Antonio (UTHSCSA) and one of the top five highest volume bladder cancer surgeons in the United States, visited DHR Health and DHR Health Institute for Research and Development to discuss collaborative efforts that will continue to enhance the ongoing partnership of advancing clinical care and research benefiting Rio Grande Valley residents.

“Dr. Robert Svatek is a nationally recognized urologic surgeon-scientist with clinical expertise in early and late phase clinical trials and urologic cancers” said Dr. Henry Ruiz, Medical Director at DHR Health Urology Institute. “Many areas of common clinical and research interests were discussed and we look forward to continuing to work with Dr. Svatek and his team at UTHSCSA to provide the highest level of care to members of our community”.

DHR Health has endowed a Distinguished Chair in Urology at UTHSCSA. The primary objective of this endowment is to create a closer and more productive partnership between the institutions, which would benefit the Rio Grande Valley community. American Cancer Society has projected that over 248,000 patients will be diagnosed with prostate cancer in 2021 and more than 34,000 will have a fatal outcome. In addition, according to the Prostate Cancer Foundation, prostate cancer is the most commonly diagnosed cancer among Hispanic/Latino men in the United States.  

- Advertisement -

“Bladder cancer is also a serious clinical challenge in the Rio Grande Valley” said Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development.   “American Cancer Society has predicted that more than 83,700 patients will be diagnosed with bladder cancer in 2021 with a very high incidence (>20%) of fatal outcome.  Given Dr. Svatek’s interest in developing innovative strategies to treat bladder cancer, our goal is to work closely with his team at UTHSCSA to partner in these innovative clinical studies”.

For more information on research studies and collaborations, please contact Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development at (956) 362-2387 or visit www.dhrresearch.org.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Unidos Contra la Diabetes to Host 2025 Mini-Symposium and Annual Dia-Beat-IT Health Fair, Nov. 5th

Unidos Contra la Diabetes (UCD) has announced that its 2025 Mini-Symposium and Annual Dia-Beat-IT Health Fair is less than a month away. Moises Arjona Jr., MS, CHWI, Collective Impact Director for UCD, reminded community partners and stakeholders of the upcoming event, encouraging participation and support.

DHR Health Breast Cancer Symposium, Oct. 11th 

To support providers in the community, the DHR Health Continuing Medical Education Department will host the Breast Cancer Symposium on Saturday, October 11, at the Edinburg Conference Center at Renaissance, located at 118 Paseo del Prado.

DHR Health Introduces Advanced PSMA-PET Imaging with Illuccix® for Prostate Cancer Care

To support early and accurate detection, DHR Health now offers Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection), a prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging tracer for the detection of prostate cancer.

TMA Supports Guidelines Recommending Younger Breast Cancer Screening Age

Women should begin routine annual mammography screenings at age 40, according to guidelines by the American College of Radiology and Society of Breast Imaging (ACR/SBI). Breast cancer screening guidelines vary on the initiation age for mammograms (40 versus 45 versus 50 years of age) and screening frequency (annual versus biennial).
- Advertisement -
×